Health
FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients – WebWire
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate…
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus…
-
Noosa News23 hours agoWhy buying a home in this surprise suburb could save you $400,000
-
Business20 hours agoBell Potter names cheap ASX dividend shares to buy now
-
Noosa News14 hours agoComing Soon: Marlowe
-
General19 hours agoAdelaide Crows star Izak Rankine at risk of AFL investigation for alleged incident in Collingwood win